Sputnik V vaccine: Dr Reddy’s working on storage temp. range

The doses will be kept outside for 15-20 minutes before being administered to the people.


Dr Reddy’s Laboratories is in the process of generating additional stability data for Russia’s C-19 vaccine Sputnik V, which has a storage condition of -18C, on 2 to 8 C, a senior official of the drug maker said on Wednesday.

Deepak Sapra, Dr Reddys Chief Executive Officer, API and Services said in a press conference that the vaccine will be imported in a frozen condition from Russian Direct Investment Fund (RDIF) with which it has an agreement to distribute 125 million human doses ( 250 million vials) in India, maintaining -18 to -22.

To read more articles about Dr Reddy’s, click here

The doses will be kept outside for 15-20 minutes before being administered to the people. “In addition to the product which is at -18C, today we are in the process of generating additional stability data on the 2 to 8C temperature range.

Medicine Injection drug vaccine
Picture: Pixabay

This data will be available in a few months, after which we will make the necessary amendment request to the regulator and request for the storage condition to be modified to 2 to 8C,” Sapra told reporters.

He said necessary cold storage infrastructure is in place to distribute Sputnik V vaccine in India, which will be available during the current quarter.

Also read:

Good storage practice of Medicines at Medical Store

Remdesivir should be supplied only to hospitals: NITI Aayog

Cipla doubles Remdesivir production to meet demand

FICCI recommends PLI-like scheme to ramp-up vaccine production

Black marketing of Remdesivir: DCGI again sounds alert to SLAs

AIOCD asks all its members not to indulge in hoarding of…

Dr Reddys Laboratories on Tuesday said it has received approval from Indian drug regulator for restricted emergency use of C-19 vaccine Sputnik in the country.

The company has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act, Dr Reddys had said in a regulatory filing.

To read more about Sputnik V Vaccine, click here

In September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of the Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the rights for distribution of the first 100 million doses in India.

Later it was enhanced to 125 million. Sapre further said the quantity can be further enhanced with mutual agreement.

Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates